Thera-SAbDab

ROSNILIMAB

>   Structural Summary
TherapeuticRosnilimab
TargetPDCD1
Heavy ChainQVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '22)Phase-II
Estimated Status (Aug '22)Active
Recorded Developmental TechnologyTBC
INN Year Proposed2022
INN Year RecommendedNone
Companies InvolvedAnaptysBio
Conditions Approvedna
Conditions ActiveAlopecia areata, Autoimmune disorders
Conditions Discontinuedna
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy